BIOMERICA INC
Close on Oct 19, 2026
- Market cap
- $5.80M
- P/E (TTM)
- –
- Dividend yield
- –
About Biomerica
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products. Its diagnostic test kits analyze patient blood, urine, nasal, or fecal samples to aid in detecting medical conditions, food intolerances, and diseases such as Helicobacter pylori infections. The company's key product offerings include the inFoods IBS diagnostic-guided therapy test, hp+detect, the EZ Detect colon disease home test, and the Aware Breast Self-Exam product. In addition to diagnostic sales, Biomerica provides contract development and manufacturing organization (CDMO) services to third parties. It primarily serves clinical laboratories, hospitals, medical research institutions, pharmaceutical firms, wholesalers, physicians' offices, drugstores, and point-of-care or over-the-counter retail customers.
The company operates its corporate headquarters, administrative offices, and primary manufacturing operations in Irvine, California. International manufacturing, assembly, and packaging activities are conducted at a facility in Mexicali, Mexico. Biomerica also maintains a European subsidiary, BioEurope GmbH, to support international sales, marketing, and distribution.
Summary of the business section of Biomerica's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIOMERICA INC
- Headquarters
- Irvine, CA
- Address
- 17571 Von Karman Avenue 92614
- Phone
- (949) 379-2875
- Website
- biomerica.com
- Employees
- 17, May 31, 2021
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- May 31
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- BMRA
- Exchange
- Nasdaq
- Shares outstanding
- 5M, Sep 28, 2026
- Public float
- $6.60M, Nov 28, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-8 reverse, Aug 29, 2025; 1-for-8 reverse, Apr 21, 2025; 1-for-2 reverse, Nov 14, 1994
- SEC CIK
- 73290
- CUSIP
- 09061H406
- ISIN
- US09061H4065
- EIN
- 95-2645573
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Zackary S. Irani | Chief Executive Officer, Director | 242,570 |
| Allen Barbieri | Executive Vice Chairman, Director | 73,542 |
| Xiaoxuan Qu | See Remarks | – |
| Gary Lu | Chief Financial Officer | 59,375 |
| Eric Chin | Director | 38,750 |
| M. Huff Gary | Director | 51,250 |
| David Moatazedi | Director | 40,625 |
| Jane Emerson | Director | 156,000 |
| Catherine Coste | Director | 137,890 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Zackary Irani | $201.03K | $177.70K | $219.85K | $11 | – |
| FY2024 Zackary Irani | $360.10K | $199.84K | $314.81K | $17 | – |
| FY2023 Zackary Irani | $141.25K | -$108.44K | $174.03K | $39 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“In addition, Biomerica de Mexico employs 17 people at its Mexico facility.”
Corporate history
Events identified from SEC filings